A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pevonedistat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 11 Jul 2019 Planned End Date changed from 30 Sep 2020 to 1 Jun 2021.
- 11 Jul 2019 Planned primary completion date changed from 30 Sep 2020 to 1 Jun 2021.
- 11 Jul 2019 Status changed from not yet recruiting to recruiting.